These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 571062)

  • 21. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
    Corey AL; Richman DP; Agius MA; Wollmann RL
    J Immunol; 1987 May; 138(10):3269-75. PubMed ID: 3494763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunopathological basis of acetylcholine receptor deficiency in myasthenia gravis.
    Engel AG
    Prog Brain Res; 1979; 49():423-34. PubMed ID: 515440
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanisms of acetylcholine receptor loss from the neuromuscular junction.
    Engel AG; Fumagalli G
    Ciba Found Symp; 1982; (90):197-224. PubMed ID: 6923808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H; Kokla A; Tzartos SJ
    Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
    Biesecker G; Gomez CM
    J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E; Klinkert WE; Wekerle H
    Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.
    Gomez CM; Wollmann RL; Richman DP
    Acta Neuropathol; 1984; 63(2):131-43. PubMed ID: 6610275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrastructural study of neuromuscular junctions in experimental autoimmune myasthenia gravis (EAMG) in rabbits.
    Arizono N; Takeoka O; Hasegawa M; Yonezawa T; Yamaguchi K
    Acta Pathol Jpn; 1985 May; 35(3):621-9. PubMed ID: 4036600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.
    De Baets MH; Verschuuren J; Daha MR; van Breda Vriesman PJ
    Immunol Res; 1988; 7(3):200-11. PubMed ID: 3264006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
    Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
    Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.
    Deng C; Goluszko E; Tüzün E; Yang H; Christadoss P
    J Immunol; 2002 Jul; 169(2):1077-83. PubMed ID: 12097416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
    Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
    Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphologic and immunologic studies in experimental autoimmune myasthenia gravis and myasthenia gravis.
    Trotter JL; Ringel SP; Cook JD; Engel WK; Eldefrawi ME; McFarlin DE
    Neurology; 1977 Dec; 27(12):1120-4. PubMed ID: 73154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myasthenia gravis as a prototype autoimmune receptor disease.
    Hoedemaekers AC; van Breda Vriesman PJ; De Baets MH
    Immunol Res; 1997; 16(4):341-54. PubMed ID: 9439759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of long-term administration of ambenonium chloride on motor end-plate fine structure and acetylcholine receptor in rat.
    Hazama R; Tsujihata M; Mori M; Takamori M; Mori K; Shibuya N
    J Neurol Sci; 1981 Jul; 51(1):69-79. PubMed ID: 7252521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
    J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes.
    Engel AG
    J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):577-89. PubMed ID: 6249893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study of antibodies to motor end-plate in ocular myasthenia gravis].
    Kinoshita I; Tsujihata M; Motomura M; Yoshimura T; Nagataki S
    Rinsho Shinkeigaku; 1991 May; 31(5):500-4. PubMed ID: 1934762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.